Chief Information Officer Bernd Bucher shares how Novartis is deploying AI across the company to drive impact for patients
NOVARTIS
Chief Information Officer Bernd Bucher shares how Novartis is deploying AI across the company to drive impact for patients
A
t Novartis, one of the world’ s largest pharmaceutical companies, scientific breakthroughs are pursued for one reason: people. The company tackles some of healthcare’ s toughest challenges, turning innovation into medicines that redefine the future for patients. Novartis is also evolving the systems and capabilities that support this work – with technology being a key enabler.
With a portfolio focused on oncology, neuroscience, cardiovascular, renal and metabolic diseases, as well as immunology, Novartis has long depended on technology that can keep pace with its science. Now, as AI begins to reshape what is possible across the industry, the company is moving to strategically embed it across the full breadth of the value chain – from how medicines are discovered, developed and delivered to patients. The aim is practical and scalable: to help teams move from data to decisions more efficiently, improve quality and support the development of medicines for patients.
Behind that effort is Bernd Bucher, Novartis’ Chief Information Officer, responsible for all technology delivery and operations across the company – from the earliest stages of drug discovery through to manufacturing, supply chain and commercial execution.
58 August 2026